Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 133

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 133
---
 to operations for the year ended December 31, 2024 and for the comparative periods presented. Sanofi has exercised the put option, pursuant to which Sanofi is contemplating entering into an agreed form share purchase agreement; that agreement, once entered into by the parties, will govern the terms for the sale and purchase of the share capital of Opella. Sanofi expects to receive a cash payment during 2025, which may reach several billion euros, upon closing of the Proposed Opella Transaction, expected in the second quarter of 2025 at the earliest, while retaining an indirect stake of around 50% in Opella. The proceeds would be used in line with Sanofi’s existing capital allocation priorities, including shareholder returns. 2024 Financial results For further information about the biopharma products we sell, and about our research and development portfolio, refer to “Item 4. Information on the Company — B. Business Overview.” Our net sales for 2024 amounted to € 41,081 million, an increase of 8.6 % from 2023 . At constant exchange rates (CER) (1) , net sales rose by 11.3 %, driven mainly by strong performances for Dupixent and increased sales of ALTUVIIIO, Lantus and Beyfortus. Net income attributable to equity holders of Sanofi amounted to € 5,560 million for 2024 , compared with € 5,400 million in 2023 , a € 160 million increase. Earnings per share was € 4.44 in 2024 , compared with € 4.31 in 2023 . Business net income (2) was € 8,912 million, down 1.8% on 2023 , while business earnings per share (business EPS (2) ) was 1.8% lower than in 2023 at € 7.12 . At the Annual General Meeting on April 30, 2025, we will ask our shareholders to approve a dividend of € 3.92 per share for the 2024 financial year, representing a payout of 55.0 % of our Business net income per share (see “— B.2. Consolidated balance sheet and debt.”). A.1.2. Impacts of competition from generics and biosimilars Some of our flagship products continued to suffer sales erosion in 2024 under the impact of competition from generics and biosimilars. We do not believe it is